All In Biotech

NDA 009386 · Waylis Therap

Myleran

Busulfan · Oral · Alkylating Drug

NovelPriority review

Last checked: Nov 19, 2026Latest source record: Dec 24, 2003 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1954

Jun 26, 1954

Approved uses

1

Original approval plus efficacy supplements

Registered trials

684

99 Phase 3, 72 recruiting

FAERS reports

15,920

15,144 serious, 4,660 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING MYLERAN is a potent drug. It should not be used unless a diagnosis of chronic myelogenous leukemia has been adequately established and the responsible physician is knowledgeable in assessing response to chemotherapy. MYLERAN can induce severe bone marrow hypoplasia. Reduce or discontinue the dosage immediately at the first sign of any unusual depression of bone marrow function as reflected by an abnormal decrease in any of the formed elements of the blood. A bone marrow examination should be performed if the bone marrow status is uncertain. SEE WARNINGS FOR INFORMATION REGARDING BUSULFAN-INDUCED LEUKEMOGENESIS IN HUMANS.

What it is approved for

From the label in effect Jan 8, 2025.

INDICATIONS AND USAGE MYLERAN (busulfan) is indicated for the palliative treatment of chronic myelogenous (myeloid, myelocytic, granulocytic) leukemia.

Therapeutic areas: Oncology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 26, 1954 Original approval · Type 1 - New Molecular Entity · priority review
1 products under this application
  • MYLERAN · BUSULFAN 2MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Busulfan" as an intervention, any sponsor and status, largest first.

All 684 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use2,098
  • product use in unapproved indication1,727
  • mucosal inflammation1,121
  • drug ineffective1,088
  • graft versus host disease922
  • venoocclusive liver disease888
  • febrile neutropenia886
  • cytomegalovirus infection881
  • acute graft versus host disease832
  • pyrexia827
  • chronic graft versus host disease645
  • cytomegalovirus infection reactivation619

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004112
2005139
200683
2007101
2008224
2009154
2010212
2011603
2012441
2013291
2014504
2015357
2016446
2017716
20181,123
20191,410
20201,532
20211,397
20221,176
20231,067
20241,437
20251,475
2026919

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Myleran (Busulfan)

2024 spending

$177K

Beneficiaries

n/a

16 claims

Per beneficiary

n/a

$278.18 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$92,104
2024$176,645

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 792 on PubMed

Sponsor: Waylis Therap

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.